Business Context and Reporting Period
Company: Biote Corp. (BTMD)
Filing Type: Form 8-K (Current Report)
Date of Report: January 26, 2026
Reporting Period: Event-specific report regarding a voluntary product recall initiated on January 26, 2026.
Key Financial Metrics and Material Changes
This filing does not provide comprehensive revenue, profit, cash flow, or debt metrics. It focuses exclusively on the financial impact of a specific event:
- Voluntary Recall: Asteria Health (a wholly-owned subsidiary) initiated a recall of hormone pellets shipped between May 20, 2025, and January 19, 2026, due to potential metal particulate matter.
- Q4 2025 Impact: The Company expects a one-time charge of approximately $1.3 million to the fourth-quarter cost of products related to the write-off of impacted inventory.
- 2026 Estimated Costs: Additional costs related to the recall in 2026 are currently estimated at approximately $1.0 million.
- Operational Impact: Management does not believe the fourth-quarter business was impacted beyond the inventory write-off and does not anticipate a material impact on the ability to service patients.
Guidance, Outlook, and Risks
Management Commentary:
- The recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).
- Affected practitioners have been notified.
- Further details on the financial impact will be provided in the fourth-quarter results report.
Risks and Contingencies:
- Regulatory Oversight: Heavy regulatory oversight in the industry and potential changes in applicable laws.
- Market Acceptance: Risks regarding the success of dietary supplements and the Biote Method in attaining market acceptance.
- Third-Party Reliance: Dependence on third parties for manufacturing support.
- Forward-Looking Uncertainties: Actual results may differ due to economic conditions, competition, geopolitical tensions, and natural disasters.
Investor Verification Checklist
- Verify the final financial impact of the recall in the upcoming Q4 2025 earnings report.
- Monitor FDA communications regarding the scope and resolution of the metal particulate matter issue.
- Review the 2024 Form 10-K and Q3 2025 Form 10-Q for broader risk factors and historical financial context not included in this 8-K.
- Assess the potential for additional unforeseen costs beyond the estimated $1.0 million for 2026.